Email Alert RSS
Volume 10 Issue 2
Sep.  2020
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2019  >  10(2): 148-151
Xi-nan SHENG, Jun GUO. Current Status and Prospects of the Treatment of Advanced Renal Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(2): 148-151. doi: 10.3969/j.issn.1674-9081.2019.02.012
Citation: Xi-nan SHENG, Jun GUO. Current Status and Prospects of the Treatment of Advanced Renal Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(2): 148-151. doi: 10.3969/j.issn.1674-9081.2019.02.012
shu

Current Status and Prospects of the Treatment of Advanced Renal Carcinoma

doi: 10.3969/j.issn.1674-9081.2019.02.012

  • Key Laboratory of Carcinogenesis and Translational, Research Ministry of Education, Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China

More Information
  • Corresponding author: GUO Jun Tel：010-88196348，E-mail：guoj307@126.com
  • Received Date: 2018-01-29
  • Publish Date: 2020-09-18
    Abstract
  • In the past decade, the emergence of targeted therapy has provided an exciting option for the treatment of renal cell carcinoma. There were 9 targeting agents approved for the treatment of unresectable or metastatic renal carcinoma by the American Food and Drug Administration(FDA). The promise of renal carcinoma immunotherapy was officially validated in December 2015 when the FDA approved Nivoliumab for the treatment of metastatic renal carcinoma. There are an increasing number of clinical trials on immune checkpoint inhibitors alone or combined with targeting agents that are now being identified and used for renal carcinoma immunotherapy. In this review, we present a brief overview of current treatments and discuss major clinical trials and data on renal carcinoma.
    • FullText(HTML)
  • loading
    • References(19)
  • [1] Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma[J]. Nat Rev Dis Primers, 2017, 3:17009.
    [2] Kumar R, Kapoor A. Current management of metastatic renal cell carcinoma: evolving new therapies[J]. Curr Opin Support Palliat Care, 2017, 11:231-237. doi:  10.1097/SPC.0000000000000277
    [3] Bedke J, Gauler T, Grünwald V, et al. Systemic therapy in metastatic renal cell carcinoma[J]. World J Urol, 2017, 35:179-188. doi:  10.1007/s00345-016-1868-5
    [4] Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma[J]. N Engl J Med, 2015, 373:1814-1823. doi:  10.1056/NEJMoa1510016
    [5] Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2016, 17:917-927. doi:  10.1016/S1470-2045(16)30107-3
    [6] Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial[J]. J Clin Oncol, 2017, 35:591-597. https://pubmed.ncbi.nlm.nih.gov/?term=28199818
    [7] Hammers HJ, Plimack ER, Infante JR, et al. Safety and Efficacy of Nivolumab in Combination with Ipilimumab in Metastatic Renal Cell Carcinoma: The Check Mate 016 Study[J]. J Clin Oncol, 2017, 35:3851-3858. doi:  10.1200/JCO.2016.72.1985
    [8] Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma[J]. N Engl J Med, 2018, 378: 1277-1290. doi:  10.1056/NEJMoa1712126
    [9] McDermott DF, Atkins MB, Motzer RJ, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma[J]. Nat Med, 2018, 24:749-757. doi:  10.1038/s41591-018-0053-3
    [10] Atkins MB, McDermott DF, Powles T, et al. IMmotion150: A phase Ⅱ study in untreated metastatic renal cell carcinoma patients of atezolizumab and bevacizumab vs and following atezolizumab or sunitinib[C]. J Clin Oncol, 2017, 35: abstract 4505.
    [11] Atkins MB, Plimack ER, Puzanov I, et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial[J]. Lancet Oncol, 2018, 19:405-415. doi:  10.1016/S1470-2045(18)30081-0
    [12] Choueiri TK, Larkin JM, Oya M, et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial[J]. Lancet Oncol, 2018, 19:451-460. doi:  10.1016/S1470-2045(18)30107-4
    [13] Lee C, Makker V, Rasco D, et al. A Phase 1b/2 Trial of Lenvatinib Plus Pembrolizumab in Patients With Renal Cell Carcinoma[C]. Ann Oncol, 2017, 28: v295-v329.
    [14] Armstrong AJ, Halabi S, Eisen T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial[J]. Lancet Oncol, 2016, 17:378-388. doi:  10.1016/S1470-2045(15)00515-X
    [15] Tannir NM, Jonasch E, Albiges L, et al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial[J]. Eur Urol, 2016, 69:866-874. doi:  10.1016/j.eururo.2015.10.049
    [16] Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma[J]. N Engl J Med, 2016, 374:135-145. doi:  10.1056/NEJMoa1505917
    [17] Campbell MT, Bilen MA, Duran C, et al. Cabozan-tinib for the treatment of patients with metastatic variant histology renal cell carcinoma (vhRCC): A retrospective study[C]. J Clin Oncol, 2017, 35: abstract 478.
    [18] Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase Ⅱ and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma[J]. J Clin Oncol, 2013, 31:181-186.
    [19] Choueiri TK, Plimack E, Arkenau HT, et al. Biomarker-Based Phase Ⅱ Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer[J]. J Clin Oncol, 2017, 35:2993-3001. doi:  10.1200/JCO.2017.72.2967
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (390) PDF downloads(975) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return